Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease
Effect of Therapeutic Hyperoxia on Maximal Oxygen Consumption and Perioperative Risk Stratification in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  3/15/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease
Effect of Therapeutic Hyperoxia on Maximal Oxygen Consumption and Perioperative Risk Stratification in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 3/15/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated:  4/4/2017
Iowa City VA Health Care System
mi
from
Iowa City, IA
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated: 4/4/2017
Iowa City VA Health Care System
mi
from
Iowa City, IA
Click here to add this to my saved trials
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated:  4/4/2017
University of Iowa
mi
from
Iowa City, IA
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated: 4/4/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects
Status: Enrolling
Updated:  4/25/2017
GSK Investigational Site
mi
from
Baltimore, MD
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects
Status: Enrolling
Updated: 4/25/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Rancho Mirage, CA
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Colorado Springs, CO
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Waterbury, CT
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Clearwater, FL
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Pensacola, FL
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Stockbridge, GA
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Stockbridge, GA
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Minneapolis, MN
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Brooklyn, NY
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Charlotte, NC
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Winston-Salem, NC
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Cincinnati, OH
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Medford, OR
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Medford, OR
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Spartanburg, SC
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
HealtheRx Survey for Pulmonary Research Registry Recruitment
HealtheRx Survey for Pulmonary Research Registry Recruitment
Status: Enrolling
Updated:  5/9/2017
University of Chicago
mi
from
Chicago, IL
HealtheRx Survey for Pulmonary Research Registry Recruitment
HealtheRx Survey for Pulmonary Research Registry Recruitment
Status: Enrolling
Updated: 5/9/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 2
mi
from
Medford, OR
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 2
mi
from
Medford, OR
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 1
mi
from
Portland, OR
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 1
mi
from
Portland, OR
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 6
mi
from
San Antonio, TX
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 6
mi
from
San Antonio, TX
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 0034
mi
from
Seattle, WA
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 0034
mi
from
Seattle, WA
Click here to add this to my saved trials
Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis
Novel Therapies for Muco-Obstructive Lung Diseases: Sustained Effects of Hypertonic Saline on Mucociliary Clearance and Clinical Tolerability in Subjects With Chronic Bronchitis
Status: Enrolling
Updated:  6/22/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis
Novel Therapies for Muco-Obstructive Lung Diseases: Sustained Effects of Hypertonic Saline on Mucociliary Clearance and Clinical Tolerability in Subjects With Chronic Bronchitis
Status: Enrolling
Updated: 6/22/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects
Novel Therapies for Muco-Obstructive Lung Diseases: A Study of Tolerability and MCC Effect of Hypertonic Saline Delivered Via the tPAD in Patients With Chronic Bronchitis
Status: Enrolling
Updated:  6/22/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects
Novel Therapies for Muco-Obstructive Lung Diseases: A Study of Tolerability and MCC Effect of Hypertonic Saline Delivered Via the tPAD in Patients With Chronic Bronchitis
Status: Enrolling
Updated: 6/22/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations
Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)
Status: Enrolling
Updated:  6/28/2017
Lancaster General Hospital
mi
from
Lancaster, PA
Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations
Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)
Status: Enrolling
Updated: 6/28/2017
Lancaster General Hospital
mi
from
Lancaster, PA
Click here to add this to my saved trials
Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations
Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)
Status: Enrolling
Updated:  6/28/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations
Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)
Status: Enrolling
Updated: 6/28/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations
Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)
Status: Enrolling
Updated:  6/28/2017
Temple University School of Medicine
mi
from
Philadelphia, PA
Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations
Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)
Status: Enrolling
Updated: 6/28/2017
Temple University School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
A Phase I, Randomized, Single-blind, Placebo-controlled, Sequential-group, Single-center Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AZD7594 Given Once Daily as Inhaled Formulation in Healthy Japanese Men
Status: Enrolling
Updated:  8/4/2017
Clinical Research Facility
mi
from
Glendale, CA
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
A Phase I, Randomized, Single-blind, Placebo-controlled, Sequential-group, Single-center Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AZD7594 Given Once Daily as Inhaled Formulation in Healthy Japanese Men
Status: Enrolling
Updated: 8/4/2017
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Efficacy of High Flow Therapy in COPD At Home
Efficacy of High Flow Therapy in COPD At Home
Status: Enrolling
Updated:  8/7/2017
Johns Hopkins University
mi
from
Baltimore, MD
Efficacy of High Flow Therapy in COPD At Home
Efficacy of High Flow Therapy in COPD At Home
Status: Enrolling
Updated: 8/7/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dietary Intake in Adults From the GA2LEN Folow-up Survey
Dietary Intake, Allergy and Respiratory Diseases in European Adults From the GA2LEN Follow-up Survey
Status: Enrolling
Updated:  8/15/2017
Johns Hopkins Bloomberg School of Public Health
mi
from
Baltimore, MD
Dietary Intake in Adults From the GA2LEN Folow-up Survey
Dietary Intake, Allergy and Respiratory Diseases in European Adults From the GA2LEN Follow-up Survey
Status: Enrolling
Updated: 8/15/2017
Johns Hopkins Bloomberg School of Public Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Intervention to Improve Function in Severe Cardiopulmonary Illness
An Intervention to Enhance Function in Severe Cardiopulmonary Illness
Status: Enrolling
Updated:  8/30/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
An Intervention to Improve Function in Severe Cardiopulmonary Illness
An Intervention to Enhance Function in Severe Cardiopulmonary Illness
Status: Enrolling
Updated: 8/30/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in COPD
Status: Enrolling
Updated:  8/31/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in COPD
Status: Enrolling
Updated: 8/31/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Achieve Clinical Research
mi
from
Birmingham, AL
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
California Medical Research Associates Inc.
mi
from
Northridge, CA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
California Medical Research Associates Inc.
mi
from
Northridge, CA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Palmtree Clinical Research Inc
mi
from
Palm Springs, CA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Palmtree Clinical Research Inc
mi
from
Palm Springs, CA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Finlay Medical Research
mi
from
Miami, FL
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Finlay Medical Research
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Progressive Medical Research
mi
from
Port Orange, FL
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Progressive Medical Research
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Columbus Regional Research Institute
mi
from
Columbus, GA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Columbus Regional Research Institute
mi
from
Columbus, GA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Southeast Regional Res Group
mi
from
Savannah, GA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Southeast Regional Res Group
mi
from
Savannah, GA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Centex Studies, Inc.
mi
from
Lake Charles, LA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Centex Studies, Inc.
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
The Clinical Research Center, LLC
mi
from
Saint Louis, MO
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
The Clinical Research Center, LLC
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Comprehensive Clinical Research
mi
from
Berlin, NJ
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Comprehensive Clinical Research
mi
from
Berlin, NJ
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
ISA Clinical Research
mi
from
Jamaica, NY
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
ISA Clinical Research
mi
from
Jamaica, NY
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Clinical Research Inst. of Southern Oregon, PC
mi
from
Medford, OR
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Clinical Research Inst. of Southern Oregon, PC
mi
from
Medford, OR
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
S. Carolina Pharmaceutical Research
mi
from
Spartanburg, SC
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
S. Carolina Pharmaceutical Research
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Centex Studies Inc
mi
from
Houston, TX
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Centex Studies Inc
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Western Washington Medical Group
mi
from
Everett, WA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Western Washington Medical Group
mi
from
Everett, WA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Premier Clinical Research
mi
from
Spokane, WA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
MultiCare Health Center of Washington
mi
from
Tacoma, WA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
MultiCare Health Center of Washington
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Centro Médico Dra de Salvo
mi
from
Buenos Aires,
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Centro Médico Dra de Salvo
mi
from
Buenos Aires,
Click here to add this to my saved trials